Videos

Catalent commits to ADCs by upping its stake in Redwood

News from Interphex 2014

Catalent commits to ADCs by upping its stake in Redwood

By Dan Stanton

Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.

Aesica says academic partnerships are key for CMOs

News from CPhI

Aesica says academic partnerships are key for CMOs

By Gareth Macdonald

UK CMO Aesica Pharmaceutical says that working with academia to access cutting edge technologies is critical for contractors that want to meet the demands of the modern drug industry.